Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline Review, H1 2019

Source: https://www.researchbymarkets.com/report/non-alcoholic-fatty-liver-disease-nafld-pipeline-review-h1-2019-268225.html

For queries regarding this report: https://www.researchbymarkets.com/sample-request/268225

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutic Products under Development, Key Players in Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Non Alcoholic Fatty Liver Disease (NAFLD) Pipeline Overview, Non Alcoholic Fatty Liver Disease (NAFLD) Pipeline, Non Alcoholic Fatty Liver Disease (NAFLD) Pipeline Assessment

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline Review, H1 2019

Summary

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline Review, H1 2019, provides an overview of the Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline landscape.

Nonalcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease. Nonalcoholic fatty liver disease is common and, for most people, causes no signs and symptoms and no complications. But in some people with nonalcoholic fatty liver disease, the fat that accumulates can cause inflammation and scarring in the liver. The most common symptoms that bring NAFLD to medical attention are malaise, fatigue, and right upper quadrant or diffuse abdominal discomfort.

Report Highlights

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Non Alcoholic Fatty Liver Disease (NAFLD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 4, 21, 13, 1, 31 and 9 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 5 molecules, respectively.

Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal).
– The pipeline guide reviews pipeline therapeutics for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal)

Reasons to buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned:
Akcea Therapeutics Inc
Ardelyx Inc
AstraZeneca Plc
Betagenon AB
BioElectron Technology Corp
Bird Rock Bio Inc
Boehringer Ingelheim GmbH
Cadila Healthcare Ltd
Can-Fite BioPharma Ltd
Carmot Therapeutics Inc
Cerenis Therapeutics Holding SA
Corcept Therapeutics Inc
Dr. Falk Pharma GmbH
DURECT Corp
Eli Lilly and Co
Enanta Pharmaceuticals Inc
Eternygen GmbH
Evgen Pharma Plc
F. Hoffmann-La Roche Ltd
Galmed Pharmaceuticals Ltd
Gemphire Therapeutics Inc
GemVax & KAEL Co Ltd
Gilead Sciences Inc
Guangdong Zhongsheng Pharmaceutical Co Ltd
Hanmi Pharmaceuticals Co Ltd
HemoShear Therapeutics, LLC
Huons Global Co Ltd
Immuron Ltd
Inventiva
Ionis Pharmaceuticals Inc
Kinomedica Pty Ltd
Kowa Co Ltd
Kyorin Pharmaceutical Co Ltd
MallInckrodt Plc
Metacrine Inc
Mina Therapeutics Ltd
Novartis AG
NuSirt Biopharma Inc
Pfizer Inc
Phenex Pharmaceuticals AG
Renova Therapeutics Inc
Ritter Pharmaceuticals Inc
Sancilio & Company Inc
Shenzhen HighTide Biopharmaceutical Ltd
T3D Therapeutics Inc
TaiwanJ Pharmaceuticals Co Ltd
TCM Biotech International Corp
Theratechnologies Inc
Tiziana Life Sciences Plc
Viking Therapeutics Inc

Contact Us:

ResearchByMarkets.com

Ritesh Tiwari, Director

enquiry@researchbymarkets.com

USA: +1-800-416-3124

https://www.researchbymarkets.com/aboutus

Follow us on Social Media:

Facebook: https://www.facebook.com/researchbymarkets/

LinkedIn: https://www.linkedin.com/company/researchbymarkets/

Twitter: https://twitter.com/ResearchByMrkts

Ritesh Tiwari is the Founder of Research By Markets. He has more than 7 years experience in the Market Research industry and a total experience spanning 18+ years. His core experience is in Sales and International Recruitments. Ritesh is a big foodie and a huge football fan, supporting Manchester United (EPL) and FC Barcelona (La Liga). He hardly misses watching any matches when these teams are playing. Get in touch with Ritesh via: enquiry@researchbymarkets.com *Industry Press Release is a part of Research By Markets.